Brain-Enhanced Delivery of Anti-Dementia Drugs

  • Marcus E. Brewster
  • Cynthia Robledo-Luiggi
  • Akio Miyakeb
  • Emil Pop
  • Nicholas Bodor
Part of the Advances in Behavioral Biology book series (ABBI, volume 36)


Senile dementia of the Alzheimer’s type (SDAT) is a slowly progressive neurological disorder which is characterized by severe and debilitating memory loss. This insidious and pernicious malady is expected to strike 20% of all individuals over the age of eighty (Bartus et al., 1982), an important and growing demographic block. At present the etiological basis of SDAT is unknown and work has been aimed at palliative treatments to increase the quality of life of those individuals stricken with the disease. In SDAT, numerous biochemical/physiological observations have suggested that a cholinergic deficit is in some way related to the disease (Becker and Giacobini, 1988 and references cited therein). Such evidence includes selective degeneration of cholinergic neurons in the basal forebrain, decreased activity and concentration of acetyl choline (ACh), choline acetyltransferase, the enzyme responsible for synthesizing ACh and acetyl cholinesterase (AChE), the enzyme responsible for ACh degradation (Sims et al., 1983). Given this biochemical basis for dementia, therapeutic approach have concentrated on bolstering the impaired cholinergic system either by agonist administration (Corkin, 1981) or by developments of AChE inhibitors. Compounds resulting from the latter scheme have offered the most potential in SDAT and include physostigmine, aminopyridines and 9amino-1,2,3,4-tetrahydroacridine (THA).


High Performance Liquid Chromatography Methyl Iodide Sodium Dithionite Quaternary Salt Pyridinium Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Allen, R., Effland, R. and Klein, J., U.S. Patent 4,578, 394 (1986).Google Scholar
  2. 2.
    Anderson, W., Simpkins, J., Woodard, P., Winwood, D., Stem, W. and Bodor, N., Anxiolytic activity of a brain delivery system for GABA. Psycopharmacol. 92 (1987) 157163.Google Scholar
  3. 3.
    Anderson, W., Simpkins, J., Brewster, M. and Bodor, N., Evidence for prolonged suppression of stress-induced release of ACTH and corticosterone with a brain-’enhanced dexamethasone redox delivery system. Neuroendocrinol. 00 (1989) 0000.Google Scholar
  4. 4.
    Bartus, R. T., Dean, R., Beer, B. and Lippa, A., The cholinergic hypothesis of geriatric memory dysfunction. Science, 217 (1982) 408–417.CrossRefGoogle Scholar
  5. 5.
    Becker, R. and Giacobini, E., Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: Clinical, pharmacological and therapeutic aspects. Drug Develop. Res., 12 (1988) 163–195.Google Scholar
  6. 6.
    Bodor, N., Redox drug delivery systems for targeting drugs to the brain. Ann. N. Y. Acad. Sci., 507 (1988) 289–306.CrossRefGoogle Scholar
  7. 7.
    Bodor, N., Shek, E. and Higuchi, T., Delivery of a quaternary pyridinium salt across the blood-brain barrier as its dihydropyridine derivative. Science, 190 (1975) 155–156.CrossRefGoogle Scholar
  8. 8.
    Bodor, N., Shek, E. and Higuchi, T., Improved delivery through biological membranes 1. Synthesis and properties of 1-methyl-1,6-dihydropyridine-2-icarbaldoxime, a prodrug of N-methyl pyridinium-2-carbaldoxime chloride. J. Med. Chem., 19 (1976) 102–108.CrossRefGoogle Scholar
  9. 9.
    Bodor, N., Farag, H. and Brewster M., Site-specific, sustained release of drugs to the brain. Science, 214 (1981) 1370–1372.CrossRefGoogle Scholar
  10. 10.
    Bodor, N. and Brewster, M., Problems of delivery of drugs to the brain. Pharmacol. Ther., 19 (1983a) 337–386.CrossRefGoogle Scholar
  11. 11.
    Bodor, N. and Brewster, M., Improved delivery through biological membranes 15. Sustained brain delivery of berberine. Eur. J. Med. Chem., 18 (1983b) 235–240.Google Scholar
  12. 12.
    Bodor, N. and Farag, H., Improved delivery through biological membranes 13. Brain specific delivery of dopamine with a dihydropyridine-pyridinium salt type redox delivery system. J. Med. Chem., 26 (1983) 528–534.CrossRefGoogle Scholar
  13. 13.
    Bodor, N. and Farag H., Improved delivery through biological membranes 14. Brain specific, sustained delivery of testosterone using a redox chemical delivery system. J. Pharm. Sci., 73 (1984) 385–389.CrossRefGoogle Scholar
  14. 14.
    Bodor, N., El Kommos, M. and Nath, C., In vivo elimination of dihydropyridine drug delivery carriers from brain and blood of rats. Bull. Pharm. Sci., Assiut Univ., 9 (1986) 14–29.Google Scholar
  15. 15.
    Bodor, N., Nakamura, T. and Brewster, M., Improved delivery through biological membranes 23. Synthesis, distribution and neurochemical effects of a tryptamine chemical delivery system. Drug Design Del., 1 (1986) 51–64.Google Scholar
  16. 16.
    Bodor, N., McCornack, J. and Brewster, M., Improved delivery through biological membranes 22. Synthesis and distribution of brain-selective estrogen delivery systems. Int. J. Pharm., 35 (1987) 47–59.CrossRefGoogle Scholar
  17. 17.
    Bodor, N., Venkatraghavan, V., Winwood, D., Estes, K. and Brewster, M., Improved delivery through biological membranes 41. Brain-enhanced delivery of chlorambucil. Int. J. Pharm., 00 (1989) 0000.Google Scholar
  18. 18.
    Brewster, M., Estes, K. and Bodor, N., Improved delivery through biological membranes 24. Synthesis, in vitro studies and in vivo characterization of brain-,specific and sustained progestin delivery system. Pharm. Res., 3 (1986) 278–285.CrossRefGoogle Scholar
  19. 19.
    Brewster, M., Estes, K. S., Perchalski, R. and Bodor, N., A dihydropyridine conjugate which generates high and sustained levels of the corresponding pyridinium salt in the brain does not exhibit neurotoxicity in cynomolgus monkeys. Neurosci. Lett., 87 (1988) 277–282.CrossRefGoogle Scholar
  20. 20.
    Corkin, S., Acetylcholine, aging and Alzheimer’s disease. Trends Neuro Sci., 12 (1981) 287–290.CrossRefGoogle Scholar
  21. 21.
    Eisner, U. and Kuthan, J., The chemistry of dihydropyridines. Chem. Rev., 72 (1972) 1–42.CrossRefGoogle Scholar
  22. 22.
    Ellman, G., Courtney, K., Andres, V. and Featherstone, R., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7 (1961) 88–95.CrossRefGoogle Scholar
  23. 23.
    Gibson, G., Pelmas, C. and Peterson, E., Cholinergic drugs and 4-aminopyridine after hypoxic induced behavior deficits. Pharm. Biochem. Behay., 18 (1983) 909–916.CrossRefGoogle Scholar
  24. 24.
    Hansi, N., A novel spasmolytic and CNS active agent: 3-(2-benzyl-methylamino ethyl) benzoic acid methyl ester hydrochloride. Experientia, 30 (1974) 271–272.CrossRefGoogle Scholar
  25. 25.
    Hansl, N., U. S. Patent 3,870, 715 (1975).Google Scholar
  26. 26.
    Hansi, N. and Mead, B., PRL-8–53: Enhanced learning and subsequent retention in humans as a result of low oral doses of new psychotropic agent. Pschopharmacol. 56 (1978) 249–253.CrossRefGoogle Scholar
  27. 27.
    Howes, J., Bodor, N., Brewster, M., Estes, K. and Eve, M., A pilot study with PR-63 in post-menopausal volunteers. J. Clin. Pharmacol., 28 (1988) 951.Google Scholar
  28. 28.
    Kaye, W., Sitaram, N., Weingartner, H., Ebert, M., Smallberg, S. and Gillin, J., Modest facilitation of memory in dementia with combined lecithin and anticholinesterase treatment. Biol. Psyciat., 17 (1982) 275–280.Google Scholar
  29. 29.
    Mattio, T., McIlhany, M., Giacobini, E. and Hallak, M., The effect of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intraventricular administration to beagle dogs. Neuropharmacol., 25 (1986) 11671177.Google Scholar
  30. 30.
    Mesulam, M., Geula, C. and Moran A., Anatomy of cholinesterase inhibition in Alzheimer’s disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann. Neurol., 22 (1987) 683–691.CrossRefGoogle Scholar
  31. 31.
    Peterson, C. and Gibson, G., 3,4-Diaminopyridine alters acetylcholine metabolism and behavior during hypoxia. J. Pharm. Exp. Ther., 222 (1982) 576–582.Google Scholar
  32. 32.
    Raghavan, K., Shek, E. and Bodor, N., Improved delivery through biological membranes 30. Synthesis and biological aspects of 1,4-dihydropyridine based chemical delivery system for brain-sustained delivery of hydroxy-CCNU. Anti—Cancer Drug Design, 2 (1987) 25–36.Google Scholar
  33. 33.
    Sims, N., Bower, D., Allen, S., Smith, C., Neary, D., Thomas D. and Davison, A., Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem., 40 (1983) 503–509.CrossRefGoogle Scholar
  34. 34.
    Summers, W., Majouski, L., Marsh, G., Tachiki, K. and Kling, A., Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer’s type. New Engl. J. Med., 315 (1986) 1241–1245.Google Scholar
  35. 35.
    Taylor, P., Anticholinesterase agents. In Gilman, A., Goodman, L. and Gilman, A. (Eds). The Pharmacological Basis of Therapeutics. Macmillan Publishing Co., Inc., New York, N.Y., 1980, pp. 100–119.Google Scholar
  36. 36.
    Wesseling H., Agostan, S., VanDam, G., Pasma, J., DeWit, D. and Hauinga, H., Effects of 4-aminopyridine in elderly patients with Alzheimer’s disease. New Engl. J. Med., 310 (1986) 988–989.Google Scholar
  37. 37.
    Wuest, H. and Sakal, E., Some derivatives of 3-pyridol with parasympathomimetic properties. J. Am. Chem. Soc., 73 (1951) 1210–1216.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Marcus E. Brewster
    • 1
  • Cynthia Robledo-Luiggi
    • 1
  • Akio Miyakeb
    • 1
  • Emil Pop
    • 1
  • Nicholas Bodor
    • 1
  1. 1.Center for Drug Design and Delivery, College of PharmacyUniversity of FloridaGainesvilleUSA

Personalised recommendations